XTalks

SEPTEMBER 8, 2020

The company has signed on to help manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus. AMRI is proud to partner with AstraZeneca in pursuit of a vaccine that could protect people against the coronavirus pandemic,” said John Ratliff, CEO of AMRI, in a statement.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

pharmaphorum

JULY 12, 2022

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA specialist Moderna. “The need for a preventive Nipah virus vaccine is significant,” he added. .

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Drug Discovery World

MAY 1, 2024

It was developed by scientists at the National Institutes of Health (NIH). “A In 2020, scientists at NIAID’s Vaccine Research Center reported that they had isolated the antibody from a volunteer who had been vaccinated with an experimental malaria vaccine. Prolonged durability in the bloodstream In 2022, the P.

Antibody 52

Antibody Clinical Trials Clinical Trials Scientist 52

Drug Discovery World

MARCH 22, 2024

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for the virus. There is no vaccine to prevent EBV infection nor a specific treatment.

Antibody 59

Antibody Vaccination Vaccine Allergies 59

Drug Discovery World

JANUARY 12, 2024

The top stories: Excitement over new antibiotics that can kill drug-resistant bacteria A novel antibiotic class targeting a major global pathogen and threat to human health has been discovered by scientists from Roche and Harvard University (Cambridge, MA, US).

Drugs 52

Drugs Immune Response Allergies Bacteria 52

Scienmag

AUGUST 31, 2020

New approach enables scientists to see how immune system responds to vaccination Flu season comes around like clockwork every year, and sooner or later everyone gets infected.

Vaccination 75

Vaccination Vaccine Scientist Allergies 75

Scienmag

MAY 12, 2021

Scripps Research scientists propose an innovative vaccine approach to protect against a troublesome family of viruses that present a major global health risk LA JOLLA, CA–Scientists at Scripps Research have unveiled a new Ebola virus vaccine design, which they say has several advantages over standard vaccine approaches for Ebola and related viruses (..)

Vaccination 47

Vaccination Vaccine Antibody Scientist 47

Scienmag

DECEMBER 9, 2020

Phase 2 trials in 1,200 adults, young children, and infants suggest new poliovirus vaccine may have the potential to overcome outbreaks caused by a mutated polio strain linked to the oral vaccine that typically circulates in areas of low immunisation coverage, and poses one of biggest barriers to eradication.

Immune Response 75

Immune Response Vaccination Vaccine Scientist 75

Scienmag

OCTOBER 6, 2020

Scientists in the US and UK publish first in-depth look at how CD4+ T cells fight SARS-CoV-2 Credit: NIAID LA JOLLA–As scientists around the world develop life-saving COVID-19 vaccines and therapies, many are still wondering exactly why the disease proves deadly in some people and mild in others.

Scientist 40

Scientist Vaccination Vaccine Development 40

Scienmag

JUNE 2, 2021

The reluctance or refusal to accept Covid-19 vaccinations can be tackled by a five-pronged strategy to addressing the behavioural and socio-demographic factors behind vaccine hesitancy.

Vaccination 46

Vaccination Vaccine Scientist Medicine 46

Scienmag

MARCH 5, 2021

Scientists at Walter Reed Army Institute of Research, in a collaboration the Duke University, have confirmed that monoclonal antibodies can be an effective tool in the global fight against malaria.

Scientist 74

Scientist Antibody Research Allergies 74

Scienmag

SEPTEMBER 1, 2020

Genetic analysis of sequences from more than 27,000 individuals infected with the coronavirus that causes COVID-19 reveals that the virus has mutated minimally since December 2019, suggesting one vaccine would be sufficient to combat global infections.

Genetic Analysis 70

Genetic Analysis Vaccination Vaccine Genetics 70

Scienmag

JANUARY 10, 2021

January 11, 2021) – To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus. Credit: Kim Ratliff, Augusta University AUGUSTA, Ga.

Vaccination 59

Vaccination Vaccine Antibody Scientist 59

Scienmag

SEPTEMBER 3, 2020

A team at the George Washington University Vaccine Research Unit has developed a controlled human hookworm infection model, accelerating the development of human hookworm vaccines WASHINGTON (August 26, 2020) – A team led by researchers at the George Washington University (GW) has established a controlled human hookworm infection (CHHI) model (..)

Vaccination 68

Vaccination Vaccine Research Development 68

The Pharma Data

JANUARY 12, 2021

12, 2021 — President-elect Joe Biden received his second dose of a coronavirus vaccine on Monday and announced that he plans to outline more of his pandemic response plan on Thursday. Biden got his first shot of the Pfizer vaccine on Dec. The Pfizer vaccine requires a second shot about three weeks after the first vaccination.

Vaccination 52

Vaccination Vaccine Scientist Allergies 52

The Pharma Data

DECEMBER 19, 2020

19, 2020 (Healthday News) — Moderna’s coronavirus vaccine was granted emergency use approval by the U.S. Food and Drug Administration on Friday, and it will now join Pfizer’s vaccine in an unprecedented national campaign to inoculate enough Americans to stem the spread of COVID-19. SATURDAY, Dec.

Vaccination 52

Vaccination Vaccine Allergies Trials 52

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. The interim analysis comprised 95 cases of symptomatic COVID-19 among volunteers.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Scienmag

JUNE 18, 2021

Recent advancements allow for novel approaches against an old enemy Scientists from the Walter Reed Army Institute of Research and Naval Medical Research Center partnered with researchers at the University of Pennsylvania and Acuitas Therapeutics to develop a novel vaccine based on mRNA technology that protects against malaria in animal models, publishing (..)

Vaccination 41

Vaccination Vaccine Scientist Development 41

The Pharma Data

MARCH 2, 2021

Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. The terms of the EUA allow use of the vaccine while more data are gathered.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 18, 2020

Food and Drug Administration said Thursday night that it will move quickly to authorize the emergency use of Moderna’s coronavirus vaccine after one of its advisory panels voted to give its blessing to the shot. “Following today’s positive advisory committee meeting outcome regarding the Moderna COVID-19 vaccine, the U.S.

Vaccination 52

Vaccination Vaccine Trials Scientist 52

Scienmag

FEBRUARY 25, 2021

Research from the California Institute of Technology shows exactly how antibodies stick to and block the Zika virus, which will inform vaccine development Credit: Image courtesy of Shannon Esswein.

Antibody 52

Antibody Scientist Vaccination Vaccine 52

Drug Discovery World

JULY 8, 2022

GSK’s ‘Vaccines for a sustainable planet’ meeting is gathering 65 experts across immunology, vaccinology, epidemiology, and policy throughout 7-8 July. . Other sessions will explore how to prioritise pathogens for antimicrobial resistance and the role of vaccines in protecting microbial diversity. . Official comments ? .

Vaccination 52

Vaccination Vaccine Allergies Bacteria 52

The Pharma Data

DECEMBER 29, 2020

29, 2020 — Vaccine maker Novavax, along with federal health researchers, announced Monday that a phase 3 trial will begin on the safety and effectiveness of another COVID-19 vaccine — the fifth shot to reach this final stage of development. Uptick in vaccine acceptance. TUESDAY, Dec.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

XTalks

DECEMBER 7, 2020

Past Few Weeks Herald Good News on the Vaccine Front. First came the news from Pfizer and its German partner BioNTech that their mRNA vaccine was 90 percent effective in preventing symptomatic COVID-19 disease. In their trial, some 30,000 patients received either two doses of Moderna’s mRNA-1273 vaccine 28 days apart or placebo.

Vaccination 52

Vaccination Vaccine Development Drugs 52

The Pharma Data

DECEMBER 31, 2020

million doses of the approved Pfizer and Moderna COVID-19 vaccines had been distributed across the United States by Monday morning, just 2.1 That’s far too slow a pace, said one official charged with spearheading the vaccination of Americans. million vaccination tally — compiled by the U.S. . THURSDAY, Dec.

Vaccination 52

Vaccination Vaccine Genetics Protein 52

The Pharma Data

DECEMBER 21, 2020

experts announced Sunday which Americans will be next in line receive a COVID-19 vaccine, health officials worldwide worried about a new strain of coronavirus that appears to spread faster than before. The two latest groups in line for a vaccine number roughly 50 million. The new COVID-19 vaccines target that spiky protein.

Vaccination 52

Vaccination Vaccine Allergies Protein 52

Scienmag

MAY 3, 2021

Researchers who elucidated key functions of RNA, the workhorse molecule of cells, will be honored in October The 2021 Warren Alpert Foundation Prize has been awarded to scientists Lynne Maquat and Joan Steitz for seminal discoveries in the biology and function of RNA, the workhorse molecule of cells.

RNA 41

RNA Scientist Research Allergies 41

The Pharma Data

DECEMBER 28, 2020

28, 2020 — When queried in polls conducted earlier this year, only about half of American adults said they planned to get any vaccine against the new coronavirus. “As soon as it is my turn to get the vaccine, I will be there front and center! Still, large pockets of skepticism and resistance to vaccination remain.

Vaccination 52

Vaccination Vaccine Scientist Allergies 52

pharmaphorum

JULY 26, 2022

Despite the obstacles, however, there are persistent efforts underway to better understand the virus with the end goal of developing a functional cure or effective vaccine against the virus. The mRNA vaccine approach is the most advanced and has been helped by the success seen in delivering a vaccine for COVID-19.

Gene Therapy 139

Gene Therapy Protein Vaccination Vaccine 139

Scienmag

JULY 26, 2021

What The Study Did: Researchers examined the safety of the second dose of the Pfizer-BioNTech or Moderna COVID-19 vaccines in patients who experienced an allergic reaction to the first dose. Authors: Kimberly G. Blumenthal, M.D., of Massachusetts General Hospital in Boston, is the corresponding author.

Vaccination 75

Vaccination Vaccine Research Scientist 75

The Pharma Data

DECEMBER 23, 2020

and the Trump Administration were close to a deal on Tuesday that would get more of the company’s coronavirus vaccine to Americans in the coming year. So far, only two pharmaceutical companies — Pfizer and Moderna — have won emergency approval for their COVID-19 vaccines. WEDNESDAY, Dec.

Vaccination 52

Vaccination Vaccine Allergies Nurses 52

Drug Discovery World

OCTOBER 28, 2022

Scientists from the National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with researchers from Walter Reed Army Institute of Research, led the study. . There is no licensed vaccine to protect against the virus. . EBV is one of the most common human viruses. EBV is one of the most common human viruses.

Antibody 52

Antibody Allergies Protein Licensing 52

Drug Discovery World

JANUARY 31, 2024

As such, the SLAS award opportunities, such as the SLAS Tony B Travel Award Program and the Student Poster Award, show the organisation’s commitment to providing a platform from the very beginning of a researcher or scientist’s career, as well as the importance of keeping new ideas pride of place.

Gene Therapy 52

Gene Therapy Allergies Scientist Gene 52

Drug Discovery World

AUGUST 1, 2022

As a result, scientists have been unable to determine whether the cells possess distinctive attributes that HIV-cure-directed therapies may exploit. Using data produced by FIND-Seq, the scientists compared the gene expression patterns of HIV-infected memory CD4+ T cells to those of HIV-uninfected memory CD4+ T cells in the same individuals.

Gene Expression 52

Gene Expression Scientist Gene Allergies 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. It is now following up with data from a small group of older adults, and they look positive. White fat, in contrast, can build up and cause obesity.

Vaccination 53

Vaccination Vaccine Research Trials 53

pharmaphorum

JULY 7, 2022

In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various emerging infectious disease threats and how it saved precious time in the work to develop a working vaccine during the current pandemic. The institute also led and funded early-stage clinical research into the vaccine candidate.

Vaccination 86

Vaccination Vaccine Development Research 86

Drug Discovery World

FEBRUARY 6, 2024

In the morning, Masaru Kanekiyo, DVM, PhD, Investigator and Chief of Molecular Immunoengineering Section of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), NIH, gave a fascinating talk on ‘Structural vaccinology for influenza: The technology behind the NIAD VRC’s nanoparticle-based vaccines.’

Life Science 64

Life Science Genome Genomics RNA 64